The level of resolution on the video was high-definition sharpness, and the foreboding shots taken by the camera guaranteed that it was both a sensation as well as its own catalyst for subsequent ...

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

In the 792-subject STRIDE study reported at the American College of Cardiology (ACC) annual meeting, Ozempic (semaglutide) achieved its main objective with a 13% improvement in maximum walking ...